Abstract

Abstract. This study was designed to investigate the hepatorenal protective effects of trévo, on cadmium-induced renal and hepatic injury in male Wistar rats.
 Methods. Fifteen healthy male Wistar rats were divided into three groups of five rats per group. Group I (control); group II (35mg/kg cadmium chloride (CdCl2); Group III (2 ml/kg trévo+ CdCl2. The rats were treated with trévo (2ml/kg orally) and administered CdCl2 3 hrs later. Twenty-four hours after the last administration rats were sacrificed and blood was collected via cardiac puncture and processed for hematological parameters and assessment of urea, creatinine (CREA), and uric acid (UA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albumin (ALB). The liver and kidney were excised and processed for markers of oxidative stress.
 Results intraperitoneal administration of 35 mg/kg of CdCl2 caused a significant increase in serum concentration of urea, CREA, UA, AST, ALT, while the concentration of ALB was significantly lower (P<0.0001). CdCl2 caused a significant reduction in packed cell volume, hemoglobin while the total white blood cell count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils were increased. Oxidative stress was significantly pronounced in the liver and kidney of rats exposed to CdCl2 as observed in the high concentration of malondialdehyde, decreased concentration of glutathione, the activity of catalase, superoxide dismutase, and glutathione-S-transferase. Pretreatment with trévo was able to significantly prevent the anemic, oxidative damage, renal and hepatic injury initiated by CdCl2.
 Conclusions. The study reveals that trévo is effective in attenuating cadmium-induced hepatorenal toxicity in male Wistar rats.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call